arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

INTENSITY THERAPEUTICS, INC.

INTS
$3.15 ▼ -0.31 (-9.09%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
5 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

INTENSITY THERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.3M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -79.6% ↗
FCF / Share $-6.81 ↗
Trailing P/E —
Price / Book 0.7x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

5-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-11.61M
↑ +28.7% —
FCF / Share Free cash flow per share
$-6.81
↑ +75.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
9
Cash Quality ↑
54

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 5 years · 19 quarters